Jan 29 (Reuters) - Abeona Therapeutics Inc:
* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA
* ABEONA THERAPEUTICS - CONTINUES TO ENGAGE FDA ON ITS PIVOTAL PHASE 3 CLINICAL TRIAL DESIGN, AND WILL PROVIDE AN UPDATE ON RMAT PROGRAM IN COMING MONTHS Source text for Eikon: Further company coverage:
